Nestlé in­vests $145M in Aim­mune’s food al­ler­gy R&D work, tak­ing the head seat at the deal ta­ble

Nestlé Health Sci­ence is mak­ing an­oth­er big in­vest­ment in an emerg­ing biotech com­pa­ny. The Bris­bane, CA-based Aim­mune $AIMT is sell­ing a whop­ping $145 mil­lion stake in the com­pa­ny to Nestlé Health Sci­ence.

The in­vest­ment gives Nestlé 15% of the biotech — 7.6 mil­lion shares at $19.20 a share — and cre­ates a new col­lab­o­ra­tion in which Nestlé will pro­vide “on­go­ing sci­en­tif­ic, reg­u­la­to­ry, and com­mer­cial ex­per­tise and ad­vice” on the biotech’s de­vel­op­ment of new ther­a­pies for food al­ler­gies. Nes­tle, mean­while, al­so gets an op­tion on get­ting the first crack at part­ner­ing with Aim­mune on its oral food al­ler­gy treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER